Travoprost/timolol fixed combination

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 6, 2008, Pages 1059-1065

  Herceg, Michael ^a   Noecker, Robert ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

DuoTrav; Eye drop; Fixed combination; Glaucoma; Ocular hypertension; Timolol; Travatan; Travoprost

Indexed keywords

BENZALKONIUM CHLORIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LATANOPROST; LATANOPROST PLUS TIMOLOL; PLACEBO; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TIMOLOL PLUS TRAVOPROST; TRAVOPROST;

BRADYCARDIA; BRONCHOSPASM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVAL HYPEREMIA; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EVENING DOSAGE; EYE BURNING; EYE IRRITATION; FATIGUE; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRICHOSIS; HYPESTHESIA; HYPOGLYCEMIA; HYPOTENSION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; MONOTHERAPY; MORNING DOSAGE; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; RETINA MACULA CYSTOID EDEMA; RETINA TEAR; REVIEW; SIDE EFFECT; SKIN PIGMENTATION; SOMNOLENCE;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; CLOPROSTENOL; DRUG COMBINATIONS; GLAUCOMA, OPEN-ANGLE; HUMANS; OCULAR HYPERTENSION; PATIENT COMPLIANCE; TIMOLOL;

EID: 42649099995     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.6.1059     Document Type: Review

References (35)

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996;80(5):38%93
2. Goldberg I. Relationship between intraocular pressure and preservation of visual field in glaucoma. Surv Ophthal 2003;48(Suppl 1):S3-7
3. Kass MA, Hener DK, Higginbotham EJ, et al.; The Ocular Hypertension Treatment Study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open angle glaucoma. Arch Ophthalmol 2002;120:71-13
4. Lichter PR, Musch DC, Gillespie BW, et al.; CIGTS Study Croup. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery Ophthalmology 2001;108:1943-53
5. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487-97
6. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005;112:487-97
7. Hoy SM, Keam SJ, Keating GM. Travoprost/timolol. Drugs Aging 2006;23:587-97
8. European Agency for the Evaluation of Medicinal Products. The morning or evening at the same time each day in DuoTrav: European Public Assessment Report (EPAR). Available from: http://www.emea.eu.int/
9. Bron AJ, Chidlow G, Melena J, Osborne NN. Beta-blocker in the treatment of glaucoma. In: Pharmacotherapy in Glaucoma. Orgul S, Flammer J, editors. Seattle: Verlag Hans Huber 2000. p. 79-113
10. Goldberg I, Cunha-Vaz J, Jakobsen JE, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2001;10:414
11. Bazzaz S, Myers JS, Katz LJ. Travoprost in the treatment of glaucoma. Expert Rev Ophthalmol 2007;2(2):177-83
12. Allingham RR, Damji D, Freedman S, et al., (eds). Shields' Textbook of Glaucoma. Philadelphia, PA: Lippincott Williams & Wilkins; 2005. p. 471-83
13. Toris CB, Zhan GL, Camras CB, McLaughlin MA. Effects of travoprost on aqueous humor dynamics in monkeys. J Glaucoma 2005;140:1-7
14. Brubaker R, Schoff EO, Nau CB, et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol 2001;131:19
15. Ziai N, Dolan JW, Kacere RD, et al. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993;111:1351
16. Toris CB, Zhan G, Fan S, et al. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure. J Glaucoma 2007;16(2):189-95
17. Barnebey H, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol 2005;140:1-7
18. Schuman JS, Katz GJ, Lewis RA, et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2005;140:242-50
19. Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/ timolol 0.5% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open-angle glaucoma or ocular hypertension. J Glaucoma 2005;14:392-9
20. Henry JC, Kessler TL, Mallick S, et al.; Travoprost/timolol Study Group. Comparison of the safety and IOP-lowering efficacy of travoprost 0.004%/ timolol 0.5% fixed combination to the concomitant administration of Xalatan and timolol 0.5% [abstr. 446]. ARVO, Fort Lauderdale; 2006
21. Topouzis F, Melamed S, Danesh-Mayer H, et al. A one-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol 2007;17:183-90
22. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703
23. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-84
24. DuBiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther 2004;26:35-47
25. Konstas AG, Vassilios PK, Ioannis EK, et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology 2007;114:653-7
26. Denis P, Andrew R, Wells D, Friren B. A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution. Eur J Ophthalmol 2006;16:407-15
27. Konstas AG, Tsironi S, Vakalis AN, et al. 24-hour intraocular pressure control obtained with evening versus morning dosed travoprost/timolol maleate fixed combination in patients with open angle glaucoma. ARVO, Fort Lauderdale; 2007, Poster 5569/B908
28. Weinreb RN. Compliance with medical treatment of glaucoma. J Glaucoma 1992;1:134-6
29. Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003;12:393-8
30. Patel SC, Spaeth GL. Compliance in patients prescribed eye drop for glaucoma. Ophthalmic Surg 1995;26:233-6
31. Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci 1974;63:333-8
32. Ventura MP, Saheb NE, Solari HP, et al. Cost considerations of the new fixed combinations for glaucoma medical therapy. J Clin Pharm Ther 2005;30:251-4
33. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004;23:490-6
34. Gasset AR, Ishii Y, Kaufman HE, et al. Cytotoxicity of ophthalmic preservatives. Am J Ophthalmol 1974;78:98-105
35. Mietz H, Niesen U, Kriegelstein GK. The effects of preservatives and antiglaucomatous medication on histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol 1994;232:561-5